Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) said Monday that they signed an agreement providing Vanda an exclusive global license to develop, manufacture, and commercialize imsidolimab.
As part of the agreement, Vanda will make an upfront payment of $10 million and an additional $5 million for the existing drug supply to AnaptysBio, which is also eligible for up to $35 million in milestone payments and a 10% royalty on net sales, according to a joint statement.
Two phase 3 trials assessing the safety and efficacy of imsidolimab in generalized pustular psoriasis have been completed, the companies said.
Vanda plans to complete technology transfer activities in 2025, the companies added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。